News
-
-
PRESS RELEASE
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease -
PRESS RELEASE
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Valneva SE reports solid full year 2024 results exceeding growth targets. Financial outlook for 2025 includes strong revenue growth and strategic investments. Key milestones and financial information discussed -
-
PRESS RELEASE
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
Valneva receives marketing authorization in the UK for the world's first chikungunya vaccine, IXCHIQ®. Single-dose vaccine for individuals 18+ provides rapid and strong immune response -
-
-
-
-
PRESS RELEASE
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
Valneva SE announces the publication of an article on the global health and economic burden of chikungunya in The British Medical Journal, revealing higher disease burden and substantial costs
